# PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca

> **NCT00467116** · PHASE1 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** gemcitabine hydrochloride
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00467116
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-08
- **Final completion:** 2007-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2012-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467116, "PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00467116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*